Organovo
| Organovo | |
|---|---|
| legal form | Incorporated |
| founding | 2007 |
| Seat | San Diego , CA USA |
| management | Taylor J. Crouch, President & CEO |
| sales | $ 1.483 million (2016) |
| Branch | pharmacy |
| Website | www.organovo.com |
Organovo is an American medical laboratory and research company that was founded in 2007, has been listed on the American technology exchange NASDAQ since 2012 under the label ONVO and is headquartered in San Diego , California . The company uses its in-house developed NovoGen MMX Bioprinter for 3D bioprinting .
Field of activity
Organovo develops functional, three-dimensional human tissue (also known as 3D bioprinting technology) for medical research and various therapeutic applications.
Organovo is developing its technology with the intention of being able to reproduce entire human organs for transplantation.
In 2015, Organovo signed an agreement with L'Oreal to use their technology to produce human skin to test the safety and effectiveness of cosmetic products.
Organovo is not yet earning any money, but is making losses. The accumulated losses of Organovo amounted to the end of 2016 about 90 million US dollars.
See also
Web links
- Organovo
- Organovo share
- Youtube: Gabor Forgacs from Organovo at TEDMED 2011 about a radical new approach to tissue engineering
Individual evidence
- ↑ a b history , Company WebSite, accessed May 13, 2017
- ↑ Management , Company WebSite, accessed May 13, 2017
- ↑ a b Investor Overview , Company WebSite, accessed May 13, 2017
- ↑ a b About , Company WebSite, accessed May 13, 2017
- ↑ Mary-Ann Russon: Organovo CEO: 3D bioprinting organs will help us get people off transplant waiting lists . In: International Business Times , July 2015. Retrieved May 13, 2017.
- ↑ Leo King: L'Oreal Seeks Quantum Leap With 3D Printed Skin . In: Forbes , May 2015. Retrieved May 13, 2017.
- ↑ Organovo and L'Oreal jointly develop 3D printed skin , 3Druck.com - The magazine for 3D printing technologies from April 8, 2015, accessed on May 13, 2017